2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2277

Midcarpal Joint Effusion Is As Common As Radiocarpal Joint Effusion In Swollen Wrists Of Patients With Rheumatoid Arthritis
Abstract Number: 2643

Midkine Is a Novel Prognostic Factor In Patients With Vasculitis Syndrome
Abstract Number: 130

Mindfulness Is Associated With Psychological Symptoms, Self-Efficacy and Quality Of Life Among Patients With Fibromyalgia
Abstract Number: 688

Minimal Clinically Important Investigations In Systemic Sclerosis
Abstract Number: 944

Mir-125a: A Novel Regulator Of IL-6 and TLR Driven Pathways In RA Pathogenesis
Abstract Number: 2860

Mir-26a, Mir-30b and HER2: New Players On Lupus Nephritis Pathogenesis
Abstract Number: 2423

Mir-27b As Biomarker and Regulator Of IL-6R Pathway In Resistant Rheumatoid Arthritis Monocyte
Abstract Number: 941

Mir-34a In Rheumatoid Arthritis: Characterisation Of Elevated Synovial Expression and Association With Treatment Resistance
Abstract Number: 1846

Mitochondrial Dysfunction Induces An Inflammatory, Tissue-Degrading, and Angiogenic Response In Normal Human Synoviocytes
Abstract Number: 1316

MMP3 As a Predictor Identifying a Subgroup Of Rheumatoid Patients Who Are Successfully Treated With Methotrexate (MTX) Alone But Still Subject To Radiographic Progression
Abstract Number: 1419

Mode Of Action Change Not Necessary After Failing The First Tumornecrosisfactor Inhibitor: Preliminary Results Of a Randomized Controlled Trial
Abstract Number: 1204

Model-Based Pharmacokinetics Of Canakinumab and Pharmacodynamics Of IL-1Beta Binding In Cryopyrin Associated Periodic Syndromes, a Step Towards Personalized Medicine
Abstract Number: 1024

Modeling The Benefit Risk Profiles Of a New Janus Kinase Inhibitor Tofacitinib Compared Tottumour Necrosis Factor Inhibitor Biologic Treatments Incorporating Conjoint Derived Patient Preference Weights
Abstract Number: 1931

Models Of Care For Arthritis: Drivers, Facilitators and Barriers To Their Development and Implementation
Abstract Number: 2601

Modified Rodnan Ultrasound Skin Score: An Ultrasound Skin Scoring Approach In Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].